GlykoGen Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Out of Business

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Out of Business

GlykoGen General Information

Description

Developer of anti-glycan antibodies designed to produce therapeutic agents for cancer treatment and diagnostics. The company's engineered monoclonal antibodies are produced using its novel immunization process to target carbohydrates found on the surface of cancerous cells, enabling healthcare organizations and pharmaceutical companies to target hard-to-treat cancers, including pancreatic cancer.

Contact Information

Website
www.glykogen.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • The James Hutton Institute
  • Craigiebuckler
  • Aberdeen AB15 8QH
  • Scotland, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • The James Hutton Institute
  • Craigiebuckler
  • Aberdeen AB15 8QH
  • Scotland, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GlykoGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Out of Business 06-Jan-2026 Completed Out of Business
6. Later Stage VC 30-Jun-2022 Completed Generating Revenue
5. Later Stage VC 12-Oct-2021 Completed Generating Revenue
4. Early Stage VC 12-Nov-2020 Completed Generating Revenue
3. Early Stage VC 16-Apr-2019 Completed Generating Revenue
2. Early Stage VC 18-Apr-2018 $495K $495K Completed Generating Revenue
1. Grant 01-Jul-2016 $141K Completed Startup
To view GlykoGen’s complete valuation and funding history, request access »

GlykoGen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary 583,554 $0.012330 $1.23 $1.23 1x $1.23 36.62%
To view GlykoGen’s complete cap table history, request access »

GlykoGen Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

GlykoGen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201611013-D0 Antibody production Inactive 24-Jun-2016

GlykoGen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

GlykoGen FAQs

  • When was GlykoGen founded?

    GlykoGen was founded in 2016.

  • Where is GlykoGen headquartered?

    GlykoGen is headquartered in Aberdeen, United Kingdom.

  • What is the size of GlykoGen?

    GlykoGen has 2 total employees.

  • What industry is GlykoGen in?

    GlykoGen’s primary industry is Drug Discovery.

  • Is GlykoGen a private or public company?

    GlykoGen is a Private company.

  • What is GlykoGen’s current revenue?

    The current revenue for GlykoGen is .

  • How much funding has GlykoGen raised over time?

    GlykoGen has raised $1.01M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process